Kaplan Fox Encourages Investors of Corcept Therapeutics, Inc. (CORT) to Contact the Firm Before Lead Plaintiff Deadline on April 21, 2026
MWN-AI** Summary
Kaplan Fox & Kilsheimer LLP is actively encouraging investors of Corcept Therapeutics, Inc. (NASDAQ: CORT) to contact the firm regarding a class action lawsuit that has been filed against the company. This lawsuit targets all individuals or entities that purchased or acquired Corcept's common stock between October 31, 2024, and December 30, 2025, inclusive. The deadline for investors to move the court to become a lead plaintiff is April 21, 2026. However, investors do not need to be lead plaintiffs to qualify for any potential recovery.
Corcept Therapeutics, a pharmaceutical company focused on developing treatments for severe endocrinological and other disorders by modulating cortisol effects, has faced significant scrutiny. The lawsuit alleges that Corcept misled its investors regarding the likelihood of FDA approval for its product candidate, relacorilant. Specifically, the complaint claims that the company's representations—that the New Drug Application (NDA) for relacorilant was strongly supported by evidence and was on track for approval—were false. In reality, the FDA had expressed concerns about the clinical evidence presented, indicating a material risk regarding the NDA's approval.
The situation escalated when, on December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter, indicating it could not approve the NDA without further evidence of effectiveness. This revelation resulted in a substantial decline in Corcept's stock price—falling over 50%, or $35.40 per share.
Kaplan Fox, with over 50 years of experience in securities litigation, encourages affected investors to reach out for guidance on the legal process. For additional information, employees can be contacted via phone or email.
MWN-AI** Analysis
As Corcept Therapeutics, Inc. (CORT) faces a class action lawsuit after a significant decline in its stock price, it's critical for investors to assess their positions and consider their options. The lawsuit stems from allegations that Corcept misled shareholders regarding the FDA's review of its lead product candidate, relacorilant. Following the FDA's Complete Response Letter on December 31, 2025, indicating concerns about the drug's efficacy, Corcept's stock plummeted by over 50%.
For investors who purchased shares during the class period from October 31, 2024, to December 30, 2025, it may be prudent to contact Kaplan Fox & Kilsheimer LLP before the April 21, 2026 lead plaintiff deadline. Even if shareholders are not interested in becoming lead plaintiffs, they can still participate in any potential recovery related to the lawsuit, which can offer a path to recoup some losses.
Investors should analyze their risk exposure in CORT. The dramatic price drop raises significant concerns about the company's future prospects, especially in the wake of a critical FDA review. Understanding the potential implications of this lawsuit and monitoring any further developments surrounding Corcept and its product pipeline is essential.
Moreover, this situation underscores the importance of regulatory approvals in the pharmaceutical sector. Investors may want to reassess their investment strategy in biotech firms, considering the inherent risks and potential volatility associated with this industry.
Ultimately, proactive engagement with legal counsel like Kaplan Fox could provide affected investors with clarity and direction during this turbulent time. Keeping informed about both the legal proceedings and the company’s operational adjustments will be essential for making well-informed decisions moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
NEW YORK, NY - February 24, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT) on behalf of all persons or entities that purchased or otherwise acquired Corcept common stock between October 31, 2024, and December 30, 2025, inclusive (the “Class Period”).
If you are a Corcept investor and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing jcampisi@kaplanfox.com or by calling (212) 329-8571.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than April 21, 2026 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
According to the complaint, “Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. One of its lead new product candidates is relacorilant, which is being developed for multiple indications, including as a treatment for patients with hypercortisolism (also known as “Cushing’s syndrome”).
The complaint further alleges that “Defendants’ Class Period representations that the relacorilant NDA was supported by powerful evidence, that it was approaching approval, and that they had no concerns about the FDA’s review were false. In truth, the FDA had repeatedly raised concerns about the adequacy of the clinical evidence supporting the NDA and, as a result, there was a known material risk that Corcept’s relacorilant NDA would not be approved.”
The complaint alleges that the “[t]he truth emerged on December 31, 2025, when Corcept revealed that the FDA had issued a Complete Response Letter . . . regarding the NDA for relacorilant as a treatment for patients with hypercortisolism. The press release issued by the Company stated that the FDA had ‘concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.’ The press release quoted Defendant Belanoff as stating that ‘[w]e are surprised and disappointed by this outcome.’ As a result of this disclosure, the price of Corcept common stock declined by $35.40 per share, or 50.4%.”
WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this investigation, please contact:
CONTACT:
Jeffrey P. Campisi
KAPLAN FOX & KILSHEIMER LLP
800 Third Avenue, 38th Floor
New York, New York 10022
(212) 329-8571
jcampisi@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1501
Oakland, California 94612
(415) 772-4704
lking@kaplanfox.com
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
https://www.kaplanfox.com/case/corcept-therapeutics-inc/
View the original release on www.newmediawire.com
Kaplan FoxFAQ**
What specific concerns did the FDA raise regarding Corcept Therapeutics Incorporated CORT's NDA for relacorilant that led to the Complete Response Letter issued on December 32025?
How might the outcome of this class action lawsuit against Corcept Therapeutics Incorporated CORT affect the company’s stock performance moving forward, especially for investors?
Can you provide insight into the potential damages or recovery process for those who purchased Corcept Therapeutics Incorporated CORT stock during the Class Period?
What evidence or documentation should affected investors gather to support their claims in the lawsuit against Corcept Therapeutics Incorporated CORT?
**MWN-AI FAQ is based on asking OpenAI questions about Corcept Therapeutics Incorporated (NASDAQ: CORT).
NASDAQ: CORT
CORT Trading
0.75% G/L:
$33.71 Last:
300,393 Volume:
$33.47 Open:
